Skip to main content

GlaxoSmithKline-gsk-logo

GlaxoSmithKline could file up to 20 new drugs for regulatory approval before 2020 as it seeks to revitalize a portfolio hit by falling sales of best-selling inhaled lung treatment Advair, the company said on Tuesday.

Seven of them may reach the market before the end of decade, it added.

{iframe}http://www.reuters.com/article/2015/11/03/us-gsk-r-d-idUSKCN0SS1B320151103{/iframe}

Search

You have successfully subscribed to the newsletter

There was an error while trying to send your request. Please try again.

BioHealth Innovation will use the information you provide on this form to be in touch with you and to provide updates and marketing.